Cervomed Inc (CRVO) Stock Price, Quote & News

Company Profile

CervoMed Inc., a a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurologic...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 744 4400

Website: www.cervomed.com

Address:

20 Park Plaza, Suite 424, Boston, United States

Mattyjc Jul. 3 at 6:02 PM

$CRVO so glad i got out of this a couple of months ago. Took a massive loss but looking at where it is now, jesus.

0 · Reply

Doki0926 Jul. 2 at 11:02 PM

$CRVO it is very disgusting that the shitfaces who told me that I’m stupid when I told that it’s over they are silent now

1 · Reply

Doki0926 Jul. 2 at 10:57 PM

$CRVO fucking idiots who believed in this shit

1 · Reply

LebanesePrince Jul. 2 at 9:29 PM

$CRVO damn it’s tanking why

1 · Reply

BPler Jul. 2 at 8:59 PM

$CRVO In a clear way super brutal, in a more hidden path great entry point for (long) institutional buyers before next news.

1 · Reply

Scorpole Jul. 2 at 7:55 PM

$CRVO 2 more months without news, SP will be back, where it started 4 months ago

1 · Reply

kaizenj Jul. 2 at 3:51 PM

$CRVO this stock definitely feels like it’s bleeding out more than other microcap biotechs waiting for their next news catalysts, but some finality with the 32-week extension data and final biomarker analysis should provide comfort for stock analysts, institutional holders and anyone unsure of Cervomed’s path forward.

1 · Reply

BPler Jul. 2 at 3:30 PM

$CRVO Added under 6, didn't have dreamed with all positive signs such a bleed out while occur. But I take the dips over time any day until next catalyst news

0 · Reply

LilyBurger Jul. 2 at 3:05 PM

$CRVO I am buying

0 · Reply

tigres1005 Jul. 2 at 1:26 PM

$CRVO Only 271K or 3.1% of shares shorted. Lowest in a long time. Sign that it's going back up.

1 · Reply

CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Mar 31, 2025, 2:34 PM EDT - 3 months ago

Biotech Stocks Q1 2025 Recap: Winners And Underperformers

CMRX CVS GERN LLY NVO SEPN

Mar 25, 2025, 8:00 AM EDT - 3 months ago

CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™)

Mar 22, 2025, 2:55 AM EDT - 3 months ago

CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats

Mar 10, 2025, 4:05 PM EDT - 4 months ago

CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies

Jan 29, 2025, 8:00 AM EST - 5 months ago

CervoMed to Present at the 8th International Lewy Body Dementia Conference

Dec 12, 2024, 7:00 AM EST - 7 months ago

CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 10, 2024, 11:37 AM EST - 7 months ago

CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets

Dec 10, 2024, 10:10 AM EST - 7 months ago

CervoMed's stock craters 77% after failed trial of treatment for rare brain disease

Dec 10, 2024, 7:33 AM EST - 7 months ago

CervoMed's dementia drug fails to meet mid-stage trial goals

Dec 10, 2024, 7:00 AM EST - 7 months ago

CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies

Nov 27, 2024, 7:00 AM EST - 7 months ago

CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia

Nov 12, 2024, 7:00 AM EST - 8 months ago

CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Nov 8, 2024, 9:55 AM EST - 8 months ago

CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup

Nov 7, 2024, 8:30 AM EST - 8 months ago

CervoMed to Participate in Upcoming Investor Conferences

Nov 4, 2024, 8:00 AM EST - 8 months ago

CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

Oct 29, 2024, 8:00 AM EDT - 8 months ago

CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference

Oct 2, 2024, 8:00 AM EDT - 9 months ago

CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference

Aug 22, 2024, 8:00 AM EDT - 11 months ago

CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies

Jul 30, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference

Jul 17, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Participate in the Emerging Growth Conference

Jul 11, 2024, 8:51 AM EDT - 1 year ago

CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024

Jun 11, 2024, 8:00 AM EDT - 1 year ago

CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies

May 20, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Appoint William Elder as Chief Financial Officer

May 15, 2024, 8:00 AM EDT - 1 year ago

CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Apr 2, 2024, 2:59 AM EDT - 1 year ago

CervoMed: H2 2024 Data For DLB Program A Major Inflection Point

Apr 1, 2024, 8:00 AM EDT - 1 year ago

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

Mar 28, 2024, 8:30 AM EDT - 1 year ago

CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors

Mar 5, 2024, 8:00 AM EST - 1 year ago

CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024

Feb 21, 2024, 8:00 AM EST - 1 year ago

CervoMed to Participate in the BIO CEO and Investor Conference

Feb 12, 2024, 8:00 AM EST - 1 year ago

CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies

Feb 7, 2024, 8:30 AM EST - 1 year ago

CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board

Feb 5, 2024, 8:00 AM EST - 1 year ago

CervoMed to Participate in the Emerging Growth Conference 67

Jan 5, 2024, 8:00 AM EST - 1 year ago

CervoMed to Participate in the Emerging Growth Conference 66

Nov 13, 2023, 7:00 AM EST - 1 year ago

CervoMed Reports Third Quarter 2023 Financial Results and Business Highlights

Oct 25, 2023, 2:50 PM EDT - 1 year ago

CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Learnings from Phase 2a Which Optimized the Design of the Phase 2b Clinical Study of Neflamapimod in Dementia with Lewy Bodies

Oct 24, 2023, 7:00 AM EDT - 1 year ago

CervoMed Announces Publications in Major Peer-Reviewed Journals That Inform on Potential of Neflamapimod as a Disease-Modifying Therapy for the Major Dementias

Oct 18, 2023, 7:00 AM EDT - 1 year ago

CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Phase 2b Neflamapimod Program for the Treatment of Patients with Dementia with Lewy Bodies

Oct 5, 2023, 7:00 AM EDT - 1 year ago

CervoMed to Present at the 2023 Roth Healthcare Opportunities Conference

Sep 5, 2023, 7:00 AM EDT - 1 year ago

CervoMed to Present at H.C. Wainwright 25th Annual Global Investment Conference

Aug 16, 2023, 1:58 PM EDT - 2 years ago

CervoMed Announces Completion of Merger with EIP Pharma

Aug 15, 2023, 4:01 PM EDT - 2 years ago

Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma

Apr 3, 2023, 2:13 PM EDT - 2 years ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HSKA, LSI, EXR, DFFN

EXR

Mar 31, 2023, 8:01 PM EDT - 2 years ago

DIFFUSION PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Diffusion Pharmaceuticals Inc. - DFFN

Mar 30, 2023, 7:00 AM EDT - 2 years ago

EIP Pharma and Diffusion Pharmaceuticals Announce Merger Agreement to Create Leading CNS-focused Company Treating Neurodegenerative Diseases

Dec 16, 2022, 6:30 AM EST - 2 years ago

Diffusion Pharmaceuticals Announces Agreement with LifeSci Special Opportunities

Dec 5, 2022, 6:30 AM EST - 2 years ago

Diffusion Pharmaceuticals Sends Letter to Stockholders Highlighting Strength of Board Leadership and Positive Progress in Strategic Review, Cautioning Stockholders Regarding LifeSci's History of Stockholder Value Destruction and Self-Dealing

Nov 14, 2022, 4:01 PM EST - 2 years ago

Diffusion Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

Nov 14, 2022, 6:30 AM EST - 2 years ago

Diffusion Pharmaceuticals Sees Significant Progress in its Strategic Review Process

Mattyjc Jul. 3 at 6:02 PM

$CRVO so glad i got out of this a couple of months ago. Took a massive loss but looking at where it is now, jesus.

0 · Reply

Doki0926 Jul. 2 at 11:02 PM

$CRVO it is very disgusting that the shitfaces who told me that I’m stupid when I told that it’s over they are silent now

1 · Reply

Doki0926 Jul. 2 at 10:57 PM

$CRVO fucking idiots who believed in this shit

1 · Reply

LebanesePrince Jul. 2 at 9:29 PM

$CRVO damn it’s tanking why

1 · Reply

BPler Jul. 2 at 8:59 PM

$CRVO In a clear way super brutal, in a more hidden path great entry point for (long) institutional buyers before next news.

1 · Reply

Scorpole Jul. 2 at 7:55 PM

$CRVO 2 more months without news, SP will be back, where it started 4 months ago

1 · Reply

kaizenj Jul. 2 at 3:51 PM

1 · Reply

BPler Jul. 2 at 3:30 PM

$CRVO Added under 6, didn't have dreamed with all positive signs such a bleed out while occur. But I take the dips over time any day until next catalyst news

0 · Reply

LilyBurger Jul. 2 at 3:05 PM

$CRVO I am buying

0 · Reply

tigres1005 Jul. 2 at 1:26 PM

$CRVO Only 271K or 3.1% of shares shorted. Lowest in a long time. Sign that it's going back up.

1 · Reply

BPler Jul. 2 at 10:41 AM

My undervalued companies picks for Q3 runner $FNKO $EVH $GPRO $CRVO $CERO Banking om Cervomed, Cero Therapeutics and GoPro the most for a potential squeeze; Funko and EVH will just run up slowly

1 · Reply

BPler Jul. 2 at 4:37 AM

$CRVO Trial enrolling started yesterday, building up potential of multi-use of their drug to widen the https://ctv.veeva.com/study/clinical-study-of-neflamapimod-in-patients-with-primary-progressive-aphasia

0 · Reply

BPler Jul. 2 at 4:25 AM

$CRVO 2 more potential catalyst ahead: CervoMed is also planning to initiate a Phase 2a trial in the nonfluent/agrammatic variant of primary progressive aphasia (a subtype of FTD) in mid-2025. Additionally, they plan to initiate a Phase 2 trial in patients recovering from ischemic stroke in the second quarter of 2025.

2 · Reply

Doki0926 Jul. 1 at 7:41 PM

$CRVO 🤣🤣🤣

0 · Reply

kaizenj Jul. 1 at 4:02 PM

$CRVO We’re officially into the 2nd half of the year. Start the countdown for the 32-week extension data. Hopefully in July, but it could be in August. They plan to submit a presentation for the AAIC in late July, hopefully they have some newer data released before the conference.

2 · Reply

Doki0926 Jul. 1 at 2:12 PM

$CRVO

0 · Reply

5layer Jul. 1 at 12:52 PM

$CRVO

0 · Reply

Doki0926 Jun. 30 at 3:34 PM

$CRVO Fuck you idiots

1 · Reply

Doki0926 Jun. 30 at 3:34 PM

$CRVO

0 · Reply

Doki0926 Jun. 30 at 3:33 PM

$CRVO "The big-mouthed experts, who have been talking for months about how there will be growth, despite of the decrease, are very quiet now. Where are the fellas who shouted on me when I told that facts are facts and it is going down!

0 · Reply

Stu_padasso Jun. 30 at 3:15 PM

$CRVO under 5 by tomorrow sold my last bit for a loss still a pretty good win iverall but eff this

1 · Reply

Doki0926 Jun. 30 at 1:24 PM

$CRVO Fall go to 2,5

0 · Reply

Market Cap	51.61M
Revenue (ttm)	9.74M
Net Income (ttm)	-16.29M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-167.25%
Debt to Equity Ratio	0.00

Volume	127,200
Avg Vol	227,098
Day's Range	N/A - N/A
Shares Out	8.70M
Stochastic %K	0%
Beta	-0.75
Analysts	Strong Sell
Price Target	$15.83